BFRI - Biofrontera stock soars 15% as FY22 revenue seen to rise over 30% Y/Y

Biofrontera (NASDAQ:BFRI) rose pre-market April 8 after it said that 2022 revenue is expected to increase by at least 30% compared to 2021. Q4 total revenue grew +6.95% Y/Y to $9.17M. Full year 2021 revenue rose by +27.86% to $24.1M. “Despite continued challenges resulting from the COVID-19 pandemic, we returned to topline growth in 2021 and sales have now recovered to near pre-pandemic levels including a seasonally strong fourth quarter," said Biofrontera CEO Erica Monaco. Biofrontera, which went public in October, reported net loss of -$14.51M, compared to -$186K in Q4 2020. Adjusted EBITDA was -$3.2M, compared to -$3K in Q4 2020. As of Dec. 31, 2021 cash and cash equivalents were $24.5M. Outlook 2022: The company said total revenues are expected to increase by at least 30% compared with 2021, including Q1 total revenues up by over 100% Y/Y and typical seasonal strength in the first and fourth quarters. The company

For further details see:

Biofrontera stock soars 15% as FY22 revenue seen to rise over 30% Y/Y